12,361 results match your criteria Journal of Hematology & Oncology [Journal]


Is DNA a better assay for residual disease in chronic myeloid leukemia?

Authors:
Jerald Radich

Haematologica 2018 Dec 30;103(12):1942-1944. Epub 2018 Nov 30.

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205583DOI Listing
December 2018

Assessment of iron deficiency.

Authors:
Chaim Hershko

Haematologica 2018 Dec 30;103(12):1939-1942. Epub 2018 Nov 30.

Professor Emeritus, Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205575DOI Listing
December 2018

Twisting the bone marrow stem cell niche.

Haematologica 2018 Dec 30;103(12):1937-1939. Epub 2018 Nov 30.

Division of Experimental Hematology and Cancer Biology, Cancer & Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.206029DOI Listing
December 2018

Identification of candidate nonsense mutations of FVIII for ribosomal readthrough therapy.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA;

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.205104DOI Listing
April 2019
1 Read

Non-genotoxic MDM2 inhibition selectively induces pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK;

Chronic lymphocytic leukemia is a clinically heterogeneous haematological malignancy which is ~90% TP53 wild-type at diagnosis. As a primary repressor of p53, targeting of mouse double-minute-2 homolog (MDM2) is an attractive therapeutic approach for non-genotoxic reactivation of p53. Since discovery of the first MDM2 inhibitor, Nutlin-3a, newer potent and bioavailable compounds have been developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.206631DOI Listing

Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes. A diagnostic accuracy study.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Centre Hospitalier Universitaire de Clermont-Ferrand, France.

Suspicion of myelodysplastic syndromes is one of the commonest reasons for bone marrow aspirate in elderly patients presenting with persistent peripheral blood cytopenia of unclear etiology. A peripheral blood assay that accurately rules out myelodysplastic syndromes would have major benefits. The diagnostic accuracy of the intraindividual robust coefficient of variation for neutrophil myeloperoxidase expression measured by flow cytometric analysis in peripheral blood was evaluated in a retrospective derivation study (44 myelodysplastic syndrome cases and 44 controls) and a prospective validation study (68 consecutive patients with suspected myelodysplastic syndromes). Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.202275DOI Listing
April 2019
1 Read

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Haematologica 2019 04 19. Epub 2019 Apr 19.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Rosai-Dorfman disease is a rare subtype of non-Langerhans cell histiocytosis. With the last major report published in 1990, there is a paucity of contemporary data on this disease. Our objective was to report the clinicopathological features, treatments and outcomes of patients seen at a tertiary referral center. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2019.219626DOI Listing
April 2019
1 Read

Ttc7a regulates haematopoietic stem cell functions while controlling the stress-induced response.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Laboratory of Normal and Pathological Homeostasis of the Immune System, Paris, France

The molecular machinery that regulates the balance between self-renewal and differentiation properties of hematopoietic stem cells has yet to be characterized in detail. Here we found that the tetratricopeptide repeat domain 7 A (Ttc7a) protein, a putative scaffold protein expressed by hematopoietic stem cells, acts as an intrinsic regulator of the proliferative response and the self- renewal potential of murine hematopoietic stem cells in vivo. Loss of Ttc7a consistently enhanced the hematopoietic stem cells' competitive repopulation ability and their intrinsic capacity to replenish the hematopoietic system after serial cell transplantations, relative to wild-type cells. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.207100DOI Listing
April 2019
1 Read

Platelet HIF-2α promotes thrombogenicity through PAI-1 synthesis and extracellular vesicle release.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, india

Oxygen-compromised environment like high altitude are associated with platelet hyperactivity. Platelets confined within the relatively impervious core of aggregate/thrombus have restricted access to oxygen, yet they continue to perform energy-intensive procoagulant activities that sustain thrombus. Therefore, studying platelet signaling under hypoxia is critical to our understanding of the mechanistic basis of thrombus stability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.217463DOI Listing

Disruption of the MBD2-NuRD complex but not MBD3-NuRD induces high level HbF expression in human erythroid cells.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Massey Cancer Center, Virginia Commonwealth University, Richmond, USA;

As high fetal hemoglobin levels ameliorate the underlying pathophysiologic defects in sickle cell anemia and β-thalassemia, understanding the mechanisms that enforce silencing of fetal hemoglobin postnatally offers the promise of effective molecular therapy. Depletion of the Nucleosome Remodeling and Deacetylase complex member MBD2 causes a 10-20 fold increase in γ-globin gene expression in adult β-globin locus yeast artificial chromosome transgenic mice. To determine the effect of MBD2 depletion in human erythroid cells, genome editing technology was utilized to knockout MBD2 in Human Umbilical cord Derived Erythroid Progenitor-2 cells resulting in γ/γ+β mRNA levels of ~50% and ~40% fetal hemoglobin by high performance liquid chromatography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.210963DOI Listing

Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA

Respiratory tract infections due to community-acquired respiratory viruses including respiratory syncytial virus, Influenza, parainfluenza virus 3 and human metapneumovirus are detected in up to 40% of allogeneic hematopoietic stem cell transplant recipients in whom they cause severe symptoms including pneumonia and bronchiolitis and can be fatal. Given the lack of effective antivirals and the data from our group demonstrating that adoptively transferred ex vivo-expanded virus-specific T cells can be clinically beneficial for the treatment of both latent (Epstein-Barr virus, cytomegalovirus, BK virus, human herpesvirus 6) and lytic (adenovirus) viruses, we investigated the potential for extending this immunotherapeutic approach to respiratory viruses. We now describe a system that rapidly generates a single preparation of polyclonal (CD4+ and CD8+) virus-specific T cells reactive against 12 antigens derived from 4 viruses (respiratory syncytial virus, Influenza, parainfluenza virus 3 and human metapneumovirus) that commonly cause post-transplant morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.206896DOI Listing

Clonal haematopoiesis and risk of acute myeloid leukemia.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Washington University School of Medicine;

Nearly all adults harbor acute myeloid leukemia-related clonal hematopoietic mutations at a variant allele fraction of ≥0.0001, yet relatively few develop hematologic malignancies. We conducted a nested analysis in the Nurses' Health Study and Health Professionals Follow-Up Study blood subcohorts, with up to 22 years of follow-up, to investigate associations of clonal mutations of ≥0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.215269DOI Listing
April 2019
2 Reads

Evolutionary trajectory of leukemic clones and its clinical implications.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Weizamnn Institute of scirence

Acute Myeloid Leukemia's ontogeny is a multistep process. It is driven both by features of the malignant clone itself, as well as by environmental pressures, making it a unique process in each individual. Recent years' technological advancements have increased our understanding about the steps that take place at the genomic level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.195289DOI Listing

Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Department of Internal Medicine, Section of Hematology, Yale School of Medicine;

Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk myelodysplastic syndromes. However, the use of several different immunosuppressive regimens, the lack of high-quality studies, and the absence of validated predictive biomarkers pose important challenges. We conducted a systematic review and meta-analysis according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines and searched MEDLINE via PubMed, Ovid EMBASE, COCHRANE registry of clinical trials (CENTRAL), and the Web of Science without language restriction from inception through September 2018 as well as relevant conference proceedings and abstracts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.219345DOI Listing

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.

Acute myeloid leukemia with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of acute myeloid leukemia cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation may improve survival if applied early during first complete remission. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.208678DOI Listing
April 2019
1 Read

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

University Hospital Brno and Faculty of Medicine, Masaryk University;

Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is therefore of critical importance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.203430DOI Listing
April 2019
1 Read

Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK;

Somatic mutations in acute myeloid leukemia are acquired sequentially and hierarchically. First, pre-leukemic mutations, such as t(8;21) that encodes AML1-ETO, are acquired within the hematopoietic stem cell compartment, while signaling pathway mutations, including K-RAS activating mutations, are late events acquired during transformation of leukemic progenitor cells and rarely detectable in hematopoietic stem cells. This raises the possibility that signaling pathway mutations are detrimental to clonal expansion of pre-leukemic hematopoietic stem cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205351DOI Listing
April 2019
1 Read

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Dept of Hematology, First Affiliated Hospital of Zhejiang Univ College of Medicine, Hangzhou, China;

Homoharringtonine, a plant alkaloid, has been reported to suppress protein synthesis and approved by U.S. Food and Drug Administration for chronic myeloid leukemia treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.208835DOI Listing
April 2019
1 Read

FLT3/ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, USA;

Acute myeloid leukemia is an aggressive hematologic neoplasm, and patients with an ITD mutation of the FLT3 receptor gene have a poor prognosis. FLT3/ITD interacts with DOCK2, a G effector protein that activates Rac1/2. Previously, we showed that knockdown of DOCK2 leads to decreased survival of FLT3/ITD leukemic cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.208843DOI Listing
April 2019
1 Read

Incidence and features of thrombosis in children with inherited antithrombin deficiency.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Hospital Universitario Morales Meseguer, Universidad de Murcia, Murcia, Spain;

Pediatric thromboembolism (≤18 years) is very rare (0.07-0.14/10,000/year) but may be more prevalent in children with severe thrombophilia (protein C, protein S or antithrombin deficiency). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.210666DOI Listing
April 2019
1 Read

Extracellular mitochondria released from traumatized brains induced platelet procoagulant activity.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Department of Medicine, University of Washington, School of Medicine, Seattle, WA, USA

Coagulopathy often develops soon after acute traumatic brain injury and its cause remains poorly understood. We have shown that injured brains release cellular microvesicles that disrupt the endothelial barrier and induce consumptive coagulopathy. Morphologically intact extracellular mitochondria accounted for 55. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.214932DOI Listing
April 2019
1 Read
5.868 Impact Factor

Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm A single-case report.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Dept. of Hematology, Vejle Hospital, University of Southern Denmark, Vejle, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.214635DOI Listing

Mental stress causes vasoconstriction in sickle cell disease and normal controls.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Children's Hospital Los Angeles;

Vaso-occlusive crisis is a hallmark of sickle cell disease where deoxygenated sickled red blood cells occlude the microvasculature. Any stimulus like mental stress that decreases microvascular blood flow will increase likelihood of red cell entrapment resulting in local vaso-occlusion and progression to vaso-occlusive crisis. Neurally mediated vasoconstriction might be the physiologic link between crisis triggers and vaso-occlusion. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.211391DOI Listing
April 2019
2 Reads

Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.

Haematologica 2019 Apr 4. Epub 2019 Apr 4.

University of Parma; Centre for Molecular and Translational Oncology

Considering that Aurora kinase inhibitors are currently under clinical investigation in hematological cancers, the identification of molecular events that limit the response to such agents is essential for enhancing clinical outcomes. Here, we discover a NF-κB-inducing kinase (NIK)-c-Abl-STAT3 signaling-centered feedback loop that restrains the efficacy of Aurora inhibitors in Multiple Myeloma. Mechanistically, we demonstrate that Aurora inhibition promotes NIK protein stabilization via downregulation of its negative regulator TRAF2; accumulated NIK converts c-Abl tyrosine kinase from a nuclear proapoptotic into a cytoplasmic antiapoptotic effector by inducing its phosphorylation at Thr735, Tyr245 and Tyr412 residues, and by entering into a trimeric complex formation with c-Abl and STAT3 increases both the transcriptional activity of STAT3 and expression of the antiapoptotic STAT3 target genes PIM1 and PIM2. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.208280DOI Listing
April 2019
8 Reads

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial.

Haematologica 2019 Apr 4. Epub 2019 Apr 4.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

This is a phase 2 dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma. The results of 4 dose levels are reported. Induction therapy consisted of 4 cycles of carfilzomib 20/27 mg/m2 (n=50), 20/36 mg/m2 (n=20), 20/45 mg/m2 (n=21) and 20/56 mg/m2 (n=20) on days 1, 2, 8, 9, 15, 16 of a 28-day cycle; thalidomide 200 mg on day 1 through 28 and dexamethasone 40 mg weekly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205476DOI Listing
April 2019
5 Reads

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production.

Haematologica 2019 Apr 4. Epub 2019 Apr 4.

Mast Cell Biology Section, Laboratory of Allergic Diseases, NIAID, NIH;

Persistent dysregulation of IL-6 production and signaling have been implicated in the pathology of various cancers. In systemic mastocytosis, increased serum levels of IL-6 associate with disease severity and progression, although the mechanisms involved are not well understood. Since systemic mastocytosis often associates with the presence in hematopoietic cells of a somatic gain-of-function variant in KIT, D816V-KIT, we examined its potential role in IL-6 upregulation. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.212126DOI Listing
April 2019
5 Reads

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.

Haematologica 2019 Apr 4. Epub 2019 Apr 4.

Weill Cornell Medicine.

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera, but their sensitivity and specificity were not tested. Moreover, red cell values do not accurately predict red cell mass, which we use to discriminate essential thrombocythemia JAK2V617F from polycythemia vera. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.213108DOI Listing
April 2019
2 Reads

Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated prediagnostic blood samples.

Haematologica 2019 Apr 4. Epub 2019 Apr 4.

Department of Radiation Sciences, Oncology, Umeå University, Sweden.

Biomarkers reliably predicting progression to multiple myeloma are lacking. Myeloma risk has been associated with low blood levels of monocyte chemotactic protein 3, macrophage inflammatory protein 1 alpha, vascular endothelial growth factor, fibroblast growth factor 2, fractalkine, and transforming growth factor alpha. In this study, we aimed to replicate these findings and study the individual dynamics of each marker in a prospective longitudinal cohort, thereby examining their potential as markers of myeloma progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.216895DOI Listing

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study.

Haematologica 2019 Apr 4. Epub 2019 Apr 4.

Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston MA

Quality of response to immunosuppressive therapy and long-term outcomes for pediatric severe aplastic anemia remain incompletely characterized. Contemporary evidence to inform treatment of relapsed or refractory severe aplastic anemia are also limited for pediatric patients. The clinical features and outcomes for 314 children treated from 2002-2014 with immunosuppressive therapy for acquired severe aplastic anemia were analyzed retrospectively from 25 institutions in the North American Pediatric Aplastic Anemia Consortium. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.206540DOI Listing
April 2019
14 Reads

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project.

Haematologica 2019 Apr;104(4):e178

Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University of Modena and Reggio Emilia, Centro Oncologico Modenese, Modena, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.218305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442952PMC

Comment to "The outcome of peripheral T-cell lymphoma patients failing first-line therapy".

Authors:
Peter Dreger

Haematologica 2019 Apr;104(4):e178

Department of Medicine V, University of Heidelberg, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.206904DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442951PMC

Asymmetric dimethylarginine - a prognostic marker for transplant outcome?

Haematologica 2019 Apr;104(4):646-647

Fred Hutchinson Cancer Research Center

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.212191DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442947PMC
April 2019
3 Reads

THROMBOTECT takes the lead.

Haematologica 2019 Apr;104(4):644-645

Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Alberta, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.209528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442948PMC